Skip to main content

The Globe and Mail

Canadian short seller makes a killing on Valeant’s stock swoon

A trading post on the floor of the New York Stock Exchange displays the Valeant Pharmaceuticals logo, Tuesday, March 15, 2016. Valeant Pharmaceuticals cut its estimates for 2016 and said it could default on some of its debt if it does not complete required financial statements by late April.

Richard Drew/AP

Short sellers take a lot of heat, particularly when someone such as Bill Ackman is on the other side of the trade, Jerome Hass says.

So when the partner at Lightwater Partners, a Toronto-based hedge-fund manager started talking about betting against Valeant, and indirectly, the famous activist investor himself, Mr. Hass heard from some of the drug company's shareholders directly. "It was certainly pointed out to me that Bill Ackman was a lot smarter than I was, and a lot richer," Mr. Hass said. "I don't dispute that, but I just disagreed on this one."

Mr. Ackman's heavy stake in Valeant has cost him billions through the company's spectacular collapse over the past six months. Mr. Hass's short position, meanwhile, has become increasingly lucrative as the stock has descended toward Tuesday's low point.

Story continues below advertisement

"We don't like crowded trades. And Valeant was a very crowded trade on the long side," he said.

Valeant has always had its doubters, but until mid-2015, its growth-through-acquisition strategy had worked so consistently that betting against its stock was a dangerous move.

The company became so big and its stock so dominant that index fund managers had to own it. To do otherwise would nearly ensure underperformance. "It was a Nortel-like situation," Mr. Hass said. "Institutional managers were plugging their noses and buying Valeant because they couldn't afford not to."

As long as the company had access to easy money to fuel acquisitions, its stock was like a "freight train," Mr. Hass said, and he was reluctant to step in front of it.

When the $11-billion (U.S.) deal to purchase Salix Pharmaceuticals closed last April, however, Valeant's borrowing capacity neared its limits, Mr. Hass said. The debt-fuelled roll-up strategy was essentially over. "Gone were the days that every time they announced an acquisition, nobody cared about the details, the share price would jump." He established a short position on the stock, which is a way to profit on its decline, at about $280 (Canadian) a share last June. But that did not prove to mark the end of the stock's momentum, which rose to nearly $350 over the following month, surpassing Royal Bank of Canada as the single most valuable Canadian stock.

"We were sweating, for sure," Mr. Hass said. But he was confident that Valeant's shares were grossly overvalued. His thesis proved true when Valeant shares proceeded to fall more than 85 per cent, capped by Tuesday's all-consuming sell-off.

"Now the risk is that the trade becomes crowded on the short side. When that happens, it's time for us to get out."

Story continues below advertisement

Report an error Licensing Options
About the Author
Investing reporter

Tim Shufelt joined the Globe and Mail in August, 2013, primarily to cover investments for Report on Business. Prior to the Globe, he worked as a staff writer at Canadian Business magazine, a business reporter at the Financial Post, and covered city news and courts for the Ottawa Citizen. More


The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨